학술논문
Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas
Document Type
article
Author
Grayson A. Herrgott; James M. Snyder; Ruicong She; Tathiane M. Malta; Thais S. Sabedot; Ian Y. Lee; Jacob Pawloski; Guilherme G. Podolsky-Gondim; Karam P. Asmaro; Jiaqi Zhang; Cara E. Cannella; Kevin Nelson; Bartow Thomas; Ana C. deCarvalho; Laura A. Hasselbach; Kelly M. Tundo; Rehnuma Newaz; Andrea Transou; Natalia Morosini; Victor Francisco; Laila M. Poisson; Dhananjay Chitale; Abir Mukherjee; Maritza S. Mosella; Adam M. Robin; Tobias Walbert; Mark Rosenblum; Tom Mikkelsen; Steven Kalkanis; Daniela P. C. Tirapelli; Daniel J. Weisenberger; Carlos G. Carlotti; Jack Rock; Ana Valeria Castro; Houtan Noushmehr
Source
Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)
Subject
Language
English
ISSN
2041-1723
Abstract
Abstract Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification of patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or monitoring. In this study, we analyze the DNA methylation levels in blood (serum and plasma) and tissue samples from 155 meningioma patients, compared to other central nervous system tumor and non-tumor entities. We discover DNA methylation markers unique to meningiomas and use artificial intelligence to create accurate and universal models for identifying and predicting meningioma recurrence, using either blood or tissue samples. Here we show that liquid biopsy is a potential noninvasive and reliable tool for diagnosing and predicting outcomes in meningioma patients. This approach can improve personalized management strategies for these patients.